SIGA Technologies, Inc.
420 Lexington Avenue
Suite 620
New York
New York
10170
United States
Tel: 212-672-9100
Fax: 212-697-3130
Website: http://www.siga.com/
Email: dkaufman@siga.com
174 articles about SIGA Technologies, Inc.
-
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020
5/6/2020
SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, reported financial results for the three months ended March 31, 2020.
-
SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Sm...
2/7/2018
If approved, TPOXX would be the first treatment for smallpox. -
SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
12/11/2017
If approved, would be the first treatment for deadly smallpox.
-
SIGA Completes Enrollment And Dosing In Final Cohort Of Phase I Study Of IV Formulation Of TPOXX® (Tecovirimat) To Treat Smallpox
4/20/2017
-
SIGA Announces Successful Completion Of Rights Offering; Funding Of Loan; Completion Of Payment Of Pharmathene Obligation
11/17/2016
-
PharmAthene, Inc. Receives Final Payment From SIGA Of $83.9 Million
11/17/2016
-
SIGA Taps a New CEO
10/13/2016
-
SIGA Announces Oct. 12 Record Date For Rights Offering
10/10/2016
-
SIGA Announces Bankruptcy Court Approval Of Transaction Under Which SIGA Will Pay PharmAthene, Inc. Claim In Full
9/21/2016
-
PharmAthene, Inc. Announces Receipt Of Payments From SIGA
9/16/2016
-
SIGA Announces Completion Of Enrollment And Dosing In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat)
8/30/2016
-
SIGA Announces Data Safety Monitoring Board (DSMB) Approval To Complete Subject Enrollment In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat)
8/9/2016
-
PharmAthene, Inc. Receives $20 Million Payment From SIGA To Extend Payment Deadline
7/11/2016
-
SIGA Announces Enrollment Of First Patients In The Final Cohort Of Phase III Study Of Tecovirimat
4/26/2016
-
SIGA Successfully Emerges from Chapter 11
4/13/2016
-
SIGA Commences Clinical Study For Intravenous (IV) Formulation Of TPOXX
3/17/2016
-
FDA Concurs On Clinical Dose For SIGA’s Tecovirimat Antiviral
2/24/2016
-
SIGA Announces That Delaware Supreme Court Affirms Court Of Chancery Opinion
12/28/2015
-
SIGA Files Reorganization Plan to Exit from Bankruptcy
12/16/2015
-
SIGA Technologies, Inc. Receives NASDAQ Delisting Notification
3/19/2015